A renaissance is in the offing for molecular imaging. It is arising from a coming together of new radiopharmaceuticals and expanded clinical applications for ones already in hand, as well as rapidly advancing scanner technology. PET will lead with a raft of new agents now making their way through clinical studies, just as the modality promises advantages that include the potential for exposing patients to less radiation, as well as a broad and underutilized installed base of PET scanners. SPECT will add to the mix with radiotracers that expand the use of this modality and scanner technologies that have the potential to remarkably improve image resolution. Read more
By Greg Freiherr